Hypotheses [Outliers]

posted by Loky do – Egypt, 2021-07-06 13:51 (626 d 11:29 ago) – Posting: # 22458
Views: 1,554

Thanks, Helmut for your reply

but I am quite confused, some products show high intrasubject variability more than anticipated or published in the literature and I think this variability affect the reliability of results, for example, I have a BE study for (lansoprazole), partially replicate design, the published intrasubject variability ~ 40% but the practical intrasubject variability we had was near 85% :confused: study protocol also stated using ema guidelines for scaling but the study failed, when I used FDA method it passes :confused: does this high variability have a role in this confusing results? also in the future protocol can I specify that if the intrasubject variability is more than 50% can I switch to the FDA method for calculation, as many authorities we submit our studies to follow ema guidelines?

Thanks in advance

Complete thread:

UA Flag
 Admin contact
22,550 posts in 4,724 threads, 1,606 registered users;
19 visitors (0 registered, 19 guests [including 9 identified bots]).
Forum time: 00:20 CET (Europe/Vienna)

That which is static and repetitive is boring.
That which is dynamic and random is confusing.
In between lies art.    John Locke

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz